Lifelong elimination of p16INK4A cells substantially delayed age-related disease, whereas late life elimination of p16INK4A cells attenuated these age-related pathologies [38], supporting the notion that cellular senescence can be successfully exploited therapeutically. This evidence concerns the gene CDKN2A and age.